Artio

Artio Medical Receives FDA Clearance for Solus Gold™ Embolization Device

Retrieved on: 
Tuesday, March 22, 2022
Risk, Blood, Bleeding, Multimedia, GLP, Cardiology, Cook, CEO, Food, Occlusion, Food and Drug Administration, MD, Industry, Anatomy, US Foods, MVP, Ambient occlusion, Physician, FDA, Patient, Pharmaceutical industry, Dentistry, Medical imaging, Neurovascular bundle, Artio

PRAIRIE VILLAGE, Kan., March 22, 2022 /PRNewswire/ -- Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, today announced it received US Food and Drug Administration (FDA) clearance for its Solus Gold Embolization Device, a next-generation product for peripheral vascular occlusion.

Key Points: 
  • PRAIRIE VILLAGE, Kan., March 22, 2022 /PRNewswire/ -- Artio Medical, Inc. , a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, today announced it received US Food and Drug Administration (FDA) clearance for its Solus GoldEmbolization Device, a next-generation product for peripheral vascular occlusion.
  • The Solus Gold Embolization Device is indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature.
  • Artio Medical is a medical device company committed to developing innovative products for the treatment of peripheral vascular, neurovascular, and cardiology diseases.
  • The Solus Gold Embolization Device combines a flexible catheter assembly and a non-porous, balloon-like gold implant for easy delivery, precise placement, and immediate vessel occlusion.

American Century Investments Hires Total Return Bond Portfolio Management Team From Aberdeen Standard

Retrieved on: 
Thursday, September 9, 2021

KANSAS CITY, Mo., Sept. 9, 2021 /PRNewswire/ -- American Century Investments, a $245 billion* global investment manager, has hired the portfolio management team responsible for Aberdeen Standard Investments' Total Return Bond strategy.

Key Points: 
  • KANSAS CITY, Mo., Sept. 9, 2021 /PRNewswire/ -- American Century Investments, a $245 billion* global investment manager, has hired the portfolio management team responsible for Aberdeen Standard Investments' Total Return Bond strategy.
  • The team will manage American Century's Total Return Bond strategy, utilizing the same methodology they employed at Aberdeen, and they will also assume additional portfolio management responsibilities.
  • Tan previously managed this team at Aberdeen, where he was head of North American Fixed Income before joining American Century in 2018.
  • In 2009, Julius Baer spun out its Americas asset management division, which included the Total Return Bond team, as Artio Global Investors.

Makana Therapeutics Announces the Appointment of Dr. Kurt Dasse to Its Board of Directors

Retrieved on: 
Wednesday, August 11, 2021
United States Air Force Scientific Advisory Board, ASAIO, Therapy, National, International Society, Patient, Pulmonary hypertension, Physiology, Tissue, Lung, Inspiration, Cell, Given Imaging, TCI, Company, Animal, Artio, Thoratec, Adult, Organ transplantation, Goal, Thermo Electron, Board, CH, Tufts University School of Medicine, Nitric oxide, Health, CEO, Miniature pig, Battelle Memorial Institute, Boston University, Abbott Laboratories, Hypothermia, Biological engineering, Ventricular assist device, Gene editing, Genetics, Kidney, Research, LLC, University, Board of directors, Medical device, Management, Pharmaceutical industry

Kurt Dasseas a new director to theMakana Therapeutics'board and especially value thedialoguewe have hadthus far.Dr.

Key Points: 
  • Kurt Dasseas a new director to theMakana Therapeutics'board and especially value thedialoguewe have hadthus far.Dr.
  • Dr. Dasse replaces Dr. Cathy Thut, who stepped down from the Makana Therapeutics Board to pursue a new opportunity in thebiotechmarket.
  • "We appreciate Cathy'scollaborativeapproach and are pleased to have worked together to enhance the company'sposition," said Joe Tector, MD, Ph.D.,Founderat Makana Therapeutics.
  • Under the scientific leadership of Dr.Joe Tector,Makana Therapeutics has achievedthe world's mostcompelling pre-clinical results in the field of xenotransplantation.

Artio Medical Welcomes Clinical, Regulatory, and Quality Executives

Retrieved on: 
Wednesday, July 14, 2021
Johnson & Johnson, Companies, Covidien, Medtronic, Tyco International, Cordis, LifeScan, Varian Medical Systems, Artio, Varian, Medical device, Economy of the United States

De Peralta comes to Artio from ExThera Medical Corporation where he served as the Vice President for Regulatory and Clinical Affairs.

Key Points: 
  • De Peralta comes to Artio from ExThera Medical Corporation where he served as the Vice President for Regulatory and Clinical Affairs.
  • Dale joins Artio with over 30 years of quality assurance experience for medical device companies.
  • Prior to Confluent Medical, Dale held quality leadership roles with BioInspire Technologies, Cordis, Covidien, LifeScan, Inc, and Varian Medical Systems.
  • "We are excited to welcome Erdie and Delane to the Artio team", said Dr. F. Nicholas Franano, President and CEO of Artio Medical.

Artio Medical Appoints Abhinav Shukla to Board of Directors

Retrieved on: 
Thursday, June 24, 2021
Abhinav, Shukla, Artio

PRAIRIE VILLAGE, Kan., June 24, 2021 /PRNewswire/ -- Artio Medical, Inc. , a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, today announces the appointment of Abhinav Shukla to the company's Board of Directors.

Key Points: 
  • PRAIRIE VILLAGE, Kan., June 24, 2021 /PRNewswire/ -- Artio Medical, Inc. , a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, today announces the appointment of Abhinav Shukla to the company's Board of Directors.
  • Prior to his Board appointment, Shukla served as a major investor and strategic advisor to the company.
  • "Artio Medical has an impressive and highly differentiated product portfolio that aims to address important unmet medical needs across several large, attractive markets," said Shukla.
  • "We are thrilled to have Abhinav join the Artio board and deepen his relationship with the company," commented F. Nicholas Franano, MD, President and CEO of Artio Medical.

Artio Medical Hires Key Sales and Marketing Leaders to Prepare for Commercial Launch of First Product in U.S.

Retrieved on: 
Tuesday, June 15, 2021
Artio, Treveri, Medical device

Weinrich and Parker have joined Artio to prepare the company for the planned U.S. market release of it first anticipated commercial product, the Solus Gold Embolization Device.

Key Points: 
  • Weinrich and Parker have joined Artio to prepare the company for the planned U.S. market release of it first anticipated commercial product, the Solus Gold Embolization Device.
  • "We are excited to welcome Jeff and Chris to the Artio team", said Dr. F. Nicholas Franano, President and CEO of Artio Medical.
  • Weinrich comes to Artio with over 30 years of senior sales executive experience in the medical device industry.
  • Artio Medical is a medical device company committed to developing innovative products for the treatment of peripheral vascular, neurovascular, and structural heart diseases.

Artio Medical Appoints Nathaniel Hagedorn to Board of Directors

Retrieved on: 
Tuesday, April 28, 2020
Artio, Treveri

FAIRWAY, Kan., April 28, 2020 /PRNewswire/ -- Artio Medical, Inc. (Artio), a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, today announced the appointment of entrepreneur and businessman Nathaniel Hagedorn to its Board of Directors.

Key Points: 
  • FAIRWAY, Kan., April 28, 2020 /PRNewswire/ -- Artio Medical, Inc. (Artio), a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, today announced the appointment of entrepreneur and businessman Nathaniel Hagedorn to its Board of Directors.
  • "We are pleased to welcome Nathaniel to Artio's Board," commented F. Nicholas Franano, President and CEO of Artio.
  • As Artio raises additional capital and launches commercial operations, we look to Nathaniel's leadership to help guide us forward."
  • Artio Medical is a medical device company committed to developing innovative endovascular products for the treatment of peripheral vascular, neurovascular, and structural heart diseases.